Results for this period
Full year1 May 2025–30 April 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The factors include the inclusion of さくら薬局グループ in the group, an increase in prescription unit prices due to prescriptions for high-priced pharmaceuticals, steady prescription volumes, steady customer traffic at stores opened in the previous fiscal year, growth in sales of Asian cosmetics and other products, strong sales of small electric fans due to the exceptionally hot summer, and successful Christmas and new-life shopping campaigns. Net income attributable to owners of the parent was also helped by the additional recognition of approximately ¥4.0 billion in deferred tax assets.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 May 2025–30 April 2026 |
| Net Sales | ¥647,834 million (YoY +41.8%) |
| Operating profit | ¥29,832 million (YoY +76.8%) |
| Ordinary income | ¥28,414 million (YoY +57.2%) |
| Profit attributable to owners of the parent | ¥17,264 million (YoY +86.4%) |
| Net income per share | ¥491.62 |
| Operating Margin | 4.6 |
| Equity ratio | End of the current fiscal period 31.2 / End of previous period 45.7 |
| Total assets | ¥509,647 million |
| Net assets | ¥159,171 million |
| Cash flows from operating activities | ¥30,872 million |
| Cash flows from investing activities | ¥-60,605 million |
| Cash flows from financing activities | ¥53,728 million |
| Cash and cash equivalents at end of period | ¥50,650 million |
| Full-year earnings forecast | Net Sales ¥721,500 million (YoY +11.4%) / Operating profit ¥32,500 million (YoY +8.9%) / Ordinary income ¥30,000 million (YoY +5.6%) / Net income ¥15,000 million (YoY -13.1%) |
| Annual Dividend Forecast | 100 yen and sen → 100 yen and sen（0.0%） |
| Payout ratio | Fiscal year ending April 2026 20.3 / Forecast for the fiscal year ending April 2027 23.4 |
| Segment revenue | Pharmacy business ¥556,424 million (YoY +44.6%), Retail Business ¥80,255 million (YoY +31.5%), Other Businesses ¥11,523 million (YoY +4.4%) |
| Segment profit | Pharmacy business ¥35,760 million (YoY +47.2%), Retail Business ¥6,528 million (YoY +35.9%), Other Businesses ¥67 million (YoY +1,277.9%) |
| Depreciation and amortization | ¥11,102 million |
| Impairment loss | ¥3,921 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥57 million, Gain on business transfer ¥174 million, Insurance surrender value ¥22 million, Gain on negative goodwill ¥74 million, Other ¥32 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥527 million, Impairment Losses ¥3,921 million, Impairment Loss on Investment Securities ¥172 million, Other ¥107 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 13 / Name of newly added company 株式会社AIN-AG1 and 12 other companies / Excluded 0 / Excluded Company Name 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 35,428,212 shares |
| Treasury Shares at Period-End | 278,291 shares |
| Factors Behind Changes in Business Performance | The factors include the inclusion of さくら薬局グループ in the group, an increase in prescription unit prices due to prescriptions for high-priced pharmaceuticals, steady prescription volumes, steady customer traffic at stores opened in the previous fiscal year, growth in sales of Asian cosmetics and other products, strong sales of small electric fans due to the exceptionally hot summer, and successful Christmas and new-life shopping campaigns. Net income attributable to owners of the parent was also helped by the additional recognition of approximately ¥4.0 billion in deferred tax assets. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The factors cited include the inclusion of さくら薬局グループ in the group, an increase in prescription unit prices due to prescriptions for high-priced pharmaceuticals, steady prescription volumes, steady customer traffic at stores opened in the previous fiscal year, growth in sales of Asian cosmetics and other products, strong sales of small electric fans due to the exceptionally hot summer, and successful Christmas and new-life shopping campaigns. In addition, approximately ¥4.0 billion in deferred tax assets was additionally recognized because the improvement in さくら薬局グループ's earnings exceeded expectations.